尿激酶联合丹参酮ⅡA治疗脑血栓形成80例分析

目的 探讨尿激酶联合丹参酮ⅡA在脑血栓形成治疗中的临床应用价值.方法 脑血栓形成患者160例,随机分为观察组(尿激酶联合丹参酮ⅡA治疗组)、对照组(尿激酶治疗组)各80例,2周为1疗程.治疗结束时对两组患者进行临床疗效统计分析.结果 经治疗,两组患者神经功能缺损情况均得到明显改善(P＜0.05)；观察组患者治疗后神经功能缺损评分明显低于对照组(P＜0.05)；观察组患者经尿激酶与丹参酮ⅡA联合治疗总有效率为95％明显高于对照组(尿激酶治疗组)的71％(P＜0.05).结论 尿激酶联合丹参酮ⅡA治疗脑血栓形成能有效改善患者神经功能缺损情况,提高患者临床治疗效果.

The value for the clinical application of urokinase combined with sodium tanshinon IIA in the treatment of cerebral thrombosis

Objective To investigate the value for the clinical application of urokinase combined with Sodi- um Tanshion IIA in the treatment of cerebral thrombosis. Methods 160 cases with cerebral thrombosis in our hospital were chosen. They were randomly divided into A group with 80 cases and B group with 80 cases. A group was the observation group（Tanshion IIA Urokinase combined treatment group）, B group was the control group （urine kinase treatment group）. 2 weeks treatment was a course. The efficacy of treatment in the two groups at the end was taken for statistical analysis. Results The neurological deficits were significantly improved in A and B group before and after treatment（ P 〈 0.05, there was statistically significant）. The neurological deficit scores in A group after treatment was significantly lower than group B （P 〈 0.05, there was statistically significant）. The total effective rate was 95% by the treatment of urokinase and Tanshion IIA in A group which was higher than group B （ P 〈 0.05, there was statistically significant difference）. Conclusion The treatment of urokinase combined with Sodium Tanshion IIA could improve neurological deficits and improve the clinical therapeutic effect.